Cecilia Hofvander
Investor Relations Contact chez BIOINVENT INTERNATIONAL AB
Provenance du réseau au premier degré de Cecilia Hofvander
Entité | Type d'entité | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 21 | |
Public Company | Biotechnology | 13 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Cecilia Hofvander via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
University of Lund | College/University | Masters Business Admin Doctorate Degree Masters Business Admin Graduate Degree Doctorate Degree Doctorate Degree | |
SkylineDx BV
SkylineDx BV Medical/Nursing ServicesHealth Services SkylineDx BV develops molecular diagnostic tests for blood cancers. The firm focuses on the development and commercialization of gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. Its products include MMprofiler and AMLprofiler. The company was founded by Dharminder S. Chahal and Bob Löwenberg in 2005 and is headquartered in Rotterdam, the Netherlands. | Medical/Nursing Services | Director of Finance/CFO Director/Board Member Chief Executive Officer | |
University of Copenhagen | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
Erasmus University Rotterdam | College/University | Undergraduate Degree Graduate Degree Doctorate Degree | |
A Bioscience Incentive AB | Director/Board Member Director/Board Member Director/Board Member | ||
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
MENDUS AB | Biotechnology | Director/Board Member Director/Board Member | |
IRLAB THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Van Herk Investments BV
Van Herk Investments BV Investment ManagersFinance Van Herk Investments BV (VHI) is the private equity investment arm of the Van Herk Groep BV, based in Rotterdam. The parent firm was established in the 1950s as a family business with a focus on real estate investments. VHI invests in listed and unlisted firms across diverse sectors primarily in The Netherlands. | Investment Managers | Director of Finance/CFO Private Equity Investor | |
MEDIVIR AB | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
ONCOLYTICS BIOTECH INC. | Biotechnology | Director/Board Member Director/Board Member | |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
SENSORION | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
Atlas Therapeutics AB
Atlas Therapeutics AB Pharmaceuticals: MajorHealth Technology Part of Alligator Bioscience AB, Atlas Therapeutics AB develops and manufactures antibody drugs. The company is based in Stockholm, Sweden. Atlas Therapeutics was acquired by Alligator Bioscience AB on October 18, 2013. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member | |
Apposite Capital LLP
Apposite Capital LLP Investment ManagersFinance Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Cancer Research UK
Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
University of Oxford | College/University | Undergraduate Degree | |
University College London | College/University | Doctorate Degree | |
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Director of Investments | |
University of Cambridge | College/University | Masters Business Admin | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member | |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member | |
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member | |
INVENTIVA | Biotechnology | Director/Board Member | |
Epsilon-3 Bio Ltd
Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member | |
Affinicon ApS
Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
OBSEVA SA | Pharmaceuticals: Major | Director/Board Member | |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member | |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal | |
IDOGEN AB (PUBL) | Biotechnology | Chief Tech/Sci/R&D Officer | |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Glionova AB
Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Institut Pasteur
Institut Pasteur Investment Trusts/Mutual FundsMiscellaneous The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
ACTIVE BIOTECH AB | Biotechnology | Director/Board Member | |
Trygga Pengar I Mobilen Sverige AB | Director/Board Member | ||
The Danish National Advanced Technology Foundation
The Danish National Advanced Technology Foundation Financial ConglomeratesFinance The Danish National Advanced Technology Foundation promotes research and innovation by providing funds. It offers private companies and universities the funds and the framework for developing new and important technologies. The company was founded in 2005 and is headquartered in Copenhagen, Denmark. | Financial Conglomerates | Director/Board Member | |
BIOPORTO A/S | Medical Specialties | Director/Board Member | |
Antag Therapeutics ApS
Antag Therapeutics ApS Pharmaceuticals: MajorHealth Technology Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman | |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | Pharmaceuticals: Major | Chairman | |
Lyhne & Co. | Director/Board Member |
Statistiques
Internationale
Danemark | 18 |
Suède | 12 |
Royaume-Uni | 8 |
Pays-Bas | 6 |
Etats-Unis | 4 |
Sectorielle
Health Technology | 33 |
Consumer Services | 7 |
Finance | 6 |
Health Services | 3 |
Commercial Services | 2 |
Opérationnelle
Director/Board Member | 160 |
Corporate Officer/Principal | 50 |
Independent Dir/Board Member | 37 |
Chairman | 26 |
Chief Tech/Sci/R&D Officer | 24 |
Relations les plus connectées
Insiders | |
---|---|
Nanna Liebach Lüneborg | 29 |
Dharminder Singh Chahal | 25 |
Thomas O. Hecht | 24 |
Bernd Seizinger | 23 |
Leonard Kruimer | 22 |
Vincent Ossipow | 22 |
Per-Olof Schrewelius | 18 |
Graham Dixon | 18 |
Kirsten Drejer | 18 |
Rein Piir | 16 |
Erik Esveld | 15 |
An van Es-Johansson | 13 |
Gayle Mills | 12 |
Martin Welschof | 12 |
Marie Svensson | 9 |
- Bourse
- Insiders
- Cecilia Hofvander
- Connexions Sociétés